BS_V96WVE3Z
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 8.672798948751643
- age_years
- 0.608
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.609
- G2M_CHECKPOINT+0.539
- MYC_TARGETS_V1+0.527
- HEDGEHOG_SIGNALING+0.353
- MYC_TARGETS_V2+0.324
- PANCREAS_BETA_CELLS+0.318
- MTORC1_SIGNALING+0.317
- MITOTIC_SPINDLE+0.301
- SPERMATOGENESIS+0.300
- OXIDATIVE_PHOSPHORYLATION+0.241
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.733
- INTERFERON_GAMMA_RESPONSE-0.629
- INFLAMMATORY_RESPONSE-0.504
- IL6_JAK_STAT3_SIGNALING-0.493
- ALLOGRAFT_REJECTION-0.489
- TNFA_SIGNALING_VIA_NFKB-0.447
- NOTCH_SIGNALING-0.444
- TGF_BETA_SIGNALING-0.411
- BILE_ACID_METABOLISM-0.400
- KRAS_SIGNALING_UP-0.395
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_S69QZAJR | medulloblastoma | — | 0.916 |
| 2 | SRR6013540 | — | cohortSQ2 | 0.914 |
| 3 | BS_WH5HDE0A | medulloblastoma | — | 0.910 |
| 4 | BS_AM70R8RG | Med | Medulloblastoma | 0.905 |
| 5 | TCGA-CQ-A4CI-01A-11R-A266-07 | — | — | 0.901 |
| 6 | SRR5088864 | — | — | 0.897 |
| 7 | BS_JZRM1S3T | medulloblastoma | — | 0.894 |
| 8 | BS_AM70R8RG | medulloblastoma | — | 0.894 |
| 9 | BS_AMZ70B6F | medulloblastoma | — | 0.894 |
| 10 | BS_81SP2HX4 | medulloblastoma | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.609 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.539 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.527 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.353 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.324 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.318 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.317 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.301 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.241 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.194 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.178 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.103 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.086 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.049 | Temsirolimus | — uncovered |
| HYPOXIA | 0.047 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.036 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.022 | Inavolisib | — uncovered |